Analyst Ratings For ABMD – ABIOMED (NASDAQ:ABMD)
Today, Goldman Sachs initiated coverage on ABMD – ABIOMED (NASDAQ:ABMD) with a Buy with a price target of $332.00.
Some recent analyst ratings include
- 4/4/2018-Goldman Sachs initiated coverage with a Buy rating.
- 2/16/2018-SunTrust Banks Reiterated Rating of Buy.
- 2/4/2018-BTIG Research Reiterated Rating of Hold.
- 2/2/2018-Guggenheim Reiterated Rating of Buy.
- 2/1/2018-Jefferies Group Reiterated Rating of Buy.
Recent Insider Trading Activity For ABMD – ABIOMED (NASDAQ:ABMD)
ABMD – ABIOMED (NASDAQ:ABMD) has insider ownership of 7.00% and institutional ownership of 88.42%.
- On 2/20/2018 Andrew J Greenfield, VP, sold 20,000 with an average share price of $270.36 per share and the total transaction amounting to $5,407,200.00.
- On 10/30/2017 Dorothy E Puhy, Director, sold 6,364 with an average share price of $179.08 per share and the total transaction amounting to $1,139,665.12.
- On 10/30/2017 Michael G Howley, VP, sold 10,000 with an average share price of $178.64 per share and the total transaction amounting to $1,786,400.00.
- On 10/2/2017 Andrew J Greenfield, VP, sold 11,282 with an average share price of $169.32 per share and the total transaction amounting to $1,910,268.24.
- On 8/30/2017 Eric A Md Rose, Director, sold 982 with an average share price of $145.17 per share and the total transaction amounting to $142,556.94.
- On 8/24/2017 Eric A Md Rose, Director, sold 23,018 with an average share price of $151.09 per share and the total transaction amounting to $3,477,789.62.
- On 8/15/2017 Paul Thomas, Director, sold 10,000 with an average share price of $154.71 per share and the total transaction amounting to $1,547,100.00.
Recent Trading Activity for ABMD – ABIOMED (NASDAQ:ABMD)
Shares of ABMD – ABIOMED closed the previous trading session at with 47275 shares trading hands.